MARKET

SBBP

SBBP

Strongbridge
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.930
+0.040
+1.38%
Pre Market: 2.980 +0.05 +1.71% 08:00 01/25 EST
OPEN
2.850
PREV CLOSE
2.890
HIGH
2.970
LOW
2.821
VOLUME
735
TURNOVER
--
52 WEEK HIGH
4.630
52 WEEK LOW
1.500
MARKET CAP
197.02M
P/E (TTM)
-3.7846
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global Acromegaly Market 2021 Analysis and Forecast to 2026 by Recent Trends, consumption by Regional data, Investigation and Growth, Developments in Manufacturing Technology and Growth Overview
Jan 19, 2021 (The Expresswire) -- Acromegaly Market provides detailed analysis of Market Overview, Drivers, Prospects, Potential Application. Also Acromegaly...
The Express Wire · 5d ago
Strongbridge Bio guides Q4 and FY20 revenue above consensus, shares up 3%
Strongbridge Biopharma (SBBP) sees Q4 Keveyis (dichlorphenamide) net product sales of ~$8.2M, consensus of $7.05M.FY 2020 Keveyis revenue is expected to be ~$30.7M, exceeding projections of $28M - $29M, and well ahead
Seekingalpha · 01/06 13:04
Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
~ Expects to Report KEVEYIS(R) (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Revenue of $ $21.7 Million ~
GlobeNewswire · 01/06 12:00
Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Revenue of $ $21.7 Million ~~ Targets Full-Year 2021 KEVE...
GlobeNewswire · 01/06 12:00
Is Strongbridge Biopharma (NASDAQ:SBBP) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Simply Wall St. · 01/04 08:29
Is SBBP A Good Stock To Buy Now?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds...
Insider Monkey · 12/14/2020 14:56
Strongbridge Biopharma Highlights Publication Of Secondary Endpoints Data From Phase 3 SONICS Study Of RECORLEV For Treatment Of Endogenous Cushing's Syndrome In The Journal, Pituitary
DUBLIN, Ireland and TREVOSE, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of
Benzinga · 11/24/2020 12:35
Strongbridge Biopharma plc Announces Publication of Secondary Endpoints Data from Phase 3 SONICS Study of RECORLEV(TM) (levoketoconazole) for the Treatment of Endogenous Cushing's Syndrome in the Journal, Pituitary
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that secondary endpoint results fr...
GlobeNewswire · 11/24/2020 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SBBP. Analyze the recent business situations of Strongbridge through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SBBP stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 110
Institutional Holdings: 39.67M
% Owned: 58.99%
Shares Outstanding: 67.24M
TypeInstitutionsShares
Increased
26
4.97M
New
24
6.97M
Decreased
23
658.62K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.68%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chief Executive Officer
John Johnson
Chief Financial Officer
Robert Lutz
Chief Operating Officer
Richard Kollender
Other
Frederic Cohen
Other
Scott Wilhoit
Secretary
Stephen Long
Lead Director/Independent Director
Garheng Kong
Independent Director
David Gill
Independent Director
Jeffrey Sherman
Independent Director
Marten Steen
Independent Director
Hilde Steineger
Independent Director
Mårten Steen
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SBBP
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
More

Webull offers kinds of Strongbridge Biopharma plc stock information, including NASDAQ:SBBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SBBP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SBBP stock methods without spending real money on the virtual paper trading platform.